C. Azzoli

发表

A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non–Small-Cell Lung Cancers

A. Drilon, H. Sugita, C. Sima, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Benefits and harms of CT screening for lung cancer: a systematic review.

D. Berry, G. Colditz, C. Azzoli, 2012, JAMA.

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

M. Kris, C. Azzoli, W. Pao, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Commentary: Preoperative gefitinib for stage II-III non-small cell lung cancer with EGFR mutation: A stich in time, or delay from stiches?

C. Azzoli, T. Ng, 2020, The Journal of thoracic and cardiovascular surgery.

Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene

William Pao, Ronglai Shen, Marc Ladanyi, 2011, Clinical Cancer Research.

Adaptive Neoadjuvant Chemotherapy Guided by 18F‐FDG PET in Resectable Non–Small Cell Lung Cancers: The NEOSCAN Trial

M. Kris, V. Rusch, C. Azzoli, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors

Akihiko Yoshizawa, C. Sima, V. Rusch, 2010, The American journal of surgical pathology.

A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors

M. Kris, C. Azzoli, V. Miller, 2010, Cancer Chemotherapy and Pharmacology.

Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer: Safety and Efficacy in a Phase 1 Trial

M. Kris, C. Azzoli, M. Ginsberg, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma

M. Kris, C. Azzoli, J. Ross, 2005, Cancer.

Gemcitabine-Induced Peripheral Edema: Report on 15 Cases and Review of the Literature

M. Kris, C. Azzoli, V. Miller, 2003, American journal of clinical oncology.

Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.

M. Kris, V. Rusch, C. Azzoli, 2014, Clinical lung cancer.

Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer?

C. Azzoli, 2005, Nature Clinical Practice Oncology.

A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.

A. Drilon, H. Sugita, C. Sima, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

M. Kris, V. Rusch, C. Azzoli, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

C. Sima, M. Kris, C. Azzoli, 2012, Clinical Cancer Research.

Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.

M. Kris, C. Azzoli, Gregory Riely, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study

C. Azzoli, L. Sequist, A. Shaw, 2021, ESMO open.

Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer

M. Kris, C. Azzoli, A. Holodny, 2010, Journal of Neuro-Oncology.

Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.

V. Seshan, C. Rudin, M. Kris, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies

C. Azzoli, W. El-Deiry, Lanlan Zhou, 2021, Frontiers in Pharmacology.

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer

M. Kris, C. Azzoli, J. Shrager, 2021, JCO precision oncology.

Commentary: Chemotherapy for stage IB large cell neuroendocrine carcinomas of lung: Convention becomes conviction.

C. Azzoli, T. Ng, 2020, The Journal of thoracic and cardiovascular surgery.

Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers

C. Sima, M. Kris, V. Rusch, 2013, Cancer Chemotherapy and Pharmacology.

A Case Series of Dose-Limiting Peripheral Edema Observed in Patients Treated with Pemetrexed

M. Kris, C. Azzoli, N. Rizvi, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

V. Seshan, M. Ladanyi, M. Kris, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.

N. Girard, M. Ladanyi, V. Rusch, 2010, Chest.

美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新

Thomas J. Smith, G. Giaccone, C. Azzoli, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

G. Giaccone, C. Azzoli, S. Temin, 2012, Journal of Oncology Practice.

Cooperation of p53 loss of function and v‐Ha‐ras in transformation of mouse keratinocyte cell lines

C. Azzoli, D. Lowry, W. Weinberg, 1998, Molecular carcinogenesis.

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Thomas J. Smith, Thomas J Smith, William Sause, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers

C. Sima, M. Zauderer, M. Kris, 2016, PloS one.

Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Molecular Tests that Matter.

C. Azzoli, Christopher Del Prete, 2020, Rhode Island medical journal.

Prediction of lung malignancy progression and survival with machine learning based on pre-treatment FDG-PET/CT

Li Yang, C. Azzoli, Z. Jiao, 2022, EBioMedicine.

Targeting lethal minimal residual disease in small cell lung cancer.

M. Kris, C. Azzoli, V. Miller, 2003, Seminars in oncology.

p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein.

C. Azzoli, A. Levine, K. Chapman, 1995, Oncogene.

10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.

M. Kris, C. Azzoli, E. Venkatraman, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

APhase 1 Study of Pralatrexate in Combinationwith Paclitaxel or Docetaxel in Patients with Advanced SolidTumors

M. Kris, C. Azzoli, E. Venkatraman, 2007 .

A Phase 1 Study of Pralatrexate in Combination with Paclitaxel or Docetaxel in Patients with Advanced Solid Tumors

M. Kris, C. Azzoli, E. Venkatraman, 2007, Clinical Cancer Research.

The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

C. Azzoli, P. Jänne, R. Govindan, 2012 .

Chemoradiation for unresectable stage III non-small cell lung cancer.

C. Azzoli, L. Gaspar, K. Price, 2008, Seminars in thoracic and cardiovascular surgery.

A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion

C. Sima, M. Kris, C. Azzoli, 2011, Cancer Chemotherapy and Pharmacology.

FOLFOX plus ziv‐aflibercept or placebo in first‐line metastatic esophagogastric adenocarcinoma: A double‐blind, randomized, multicenter phase 2 trial

Jeffrey W. Clark, C. Azzoli, J. Meyerhardt, 2019, Cancer.

Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).

C. Azzoli, M. Mino‐Kenudson, D. Haber, 2018 .

SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.

M. Kris, C. Azzoli, P. Jänne, 2014 .

p53 gene dosage modifies growth and malignant progression of keratinocytes expressing the v-rasHa oncogene.

C. Azzoli, S. Yuspa, W. Weinberg, 1994, Cancer research.

Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).

C. Azzoli, W. El-Deiry, Lanlan Zhou, 2022, American journal of cancer research.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a randomized phase IIb study estimating overall survival of pralatrexate versus erlotinib in platinum-pretreated NSCLC.

C. Azzoli, P. Zatloukal, G. Weems, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab

C. Azzoli, T. Dipetrillo, J. Hepel, 2022, Advances in radiation oncology.

Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer

C. Azzoli, H. Willers, F. Xia, 2013, Cancer journal.

A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors

M. Kris, C. Azzoli, N. Kemeny, 2006, Cancer Chemotherapy and Pharmacology.

Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small-Cell Lung Cancer Guideline.

M. Kris, C. Azzoli, M. Somerfield, 2007, Journal of oncology practice.

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

S. Digumarthy, Y. Yagi, C. Azzoli, 2016, Clinical Cancer Research.

Practical Value of Molecular Pathology in Stage I–III Lung Cancer: Implications for the Clinical Surgeon

C. Azzoli, 2015, Annals of Surgical Oncology.

Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors.

S. Baylin, C. Azzoli, B. Nelkin, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.

M. Kris, C. Azzoli, Steven H. Lin, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report

N. Girard, A. Viale, M. Ladanyi, 2010, Clinical Cancer Research.

Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

M. Ladanyi, C. Azzoli, W. Pao, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer.

C. Azzoli, A. Farago, 2017, Translational lung cancer research.

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations

M. Ladanyi, M. Kris, C. Azzoli, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

C. Sima, M. Kris, C. Azzoli, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer

M. Kris, C. Azzoli, J. Chaft, 2021, Nature Reviews Clinical Oncology.

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

M. Ladanyi, C. Sima, M. Kris, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Markus Riester, Cyril H Benes, S. Digumarthy, 2018, JCO precision oncology.

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib

M. Ladanyi, C. Sima, M. Kris, 2011, Clinical Cancer Research.

Genotyping lung cancer is an investment in the future.

E. Lamont, C. Azzoli, L. Sequist, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

William Pao, Maria E Arcila, Gregory J Riely, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

M. Lawrence, S. Digumarthy, C. Azzoli, 2020, Clinical Cancer Research.

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab

C. Sima, M. Kris, V. Rusch, 2013, Cancer Chemotherapy and Pharmacology.

Pulmonary toxicity associated with erlotinib.

M. Kris, C. Azzoli, W. Travis, 2007, Chest.

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

G. Giaccone, C. Azzoli, S. Temin, 2010, Journal of Oncology Practice.

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

William Pao, Valerie Rusch, Christopher Azzoli, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.

Jeffrey W. Clark, A. Iafrate, C. Azzoli, 2020, The oncologist.

A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer

C. Rudin, M. Kris, C. Azzoli, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.

M. Ladanyi, C. Azzoli, Melissa L. Johnson, 2011, Lung cancer.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

C. Azzoli, L. Sequist, A. Shaw, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Practice Guideline Update on Chemotherapy for Stage IV Non – Small-Cell Lung Cancer

Thomas J. Smith, G. Giaccone, C. Azzoli, 2009 .

[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

Thomas J. Smith, G. Giaccone, C. Azzoli, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed.

M. Kris, C. Azzoli, D. Pfister, 2007, Journal of the National Cancer Institute.

Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer: A Time for Excitement and Equipoise

M. Kris, C. Azzoli, W. Pao, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

M. Kris, C. Azzoli, W. Pao, 2011, Clinical Cancer Research.

Adjuvant therapy for a 3.9-cm adenocarcinoma of the lung.

C. Azzoli, R. Heist, 2013, The oncologist.

AdjuvantTherapyfora3.9-cmAdenocarcinomaoftheLung

C. Azzoli, R. Heist, 2013 .

Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer

M. Kris, C. Azzoli, T. Lynch, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Sean P. Brown, C. Azzoli, D. Cahill, 2018, Cancer discovery.

Economic and social changes among distressed family caregivers of lung cancer patients

C. Azzoli, N. Hanna, V. Champion, 2013, Supportive Care in Cancer.

A phase I trial of perillyl alcohol in patients with advanced solid tumors

M. Kris, C. Azzoli, V. Miller, 2003, Cancer Chemotherapy and Pharmacology.

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer

M. Kris, C. Azzoli, W. Pao, 2007, Cancer.

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping

C. Azzoli, L. Sequist, A. Shaw, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer.

C. Azzoli, Justin P Huynh, C. Collins, 2021, European journal of cancer.

Neoadjuvant Chemotherapy for Resectable Non-Small Cell Lung Cancer

C. Azzoli, K. Pisters, 2014 .

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers

C. Sima, M. Kris, V. Rusch, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.

M. Kris, C. Azzoli, M. Somerfield, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy for resected non-small-cell lung cancer--ANITA takes the stage.

C. Azzoli, 2006, The Lancet. Oncology.

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors

M. Kris, C. Azzoli, N. Rosen, 2007, Cancer Chemotherapy and Pharmacology.

Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib

C. Sima, M. Kris, C. Azzoli, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Optimal Use of Antiemetics in the Outpatient Setting

M. Kris, C. Azzoli, 2002 .

Trastuzumab in the treatment of non-small cell lung cancer.

M. Kris, C. Azzoli, V. Miller, 2002, Seminars in oncology.

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma

A. Iafrate, C. Azzoli, Haiyu Zhou, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer

William Pao, M. Kris, C. Azzoli, 2006, Cancer.

Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.

G. Giaccone, C. Azzoli, R. Govindan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MET amplification (amp) as a resistance mechanism to osimertinib.

C. Azzoli, L. Sequist, A. Shaw, 2017 .

Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial

M. Kris, C. Azzoli, W. Pao, 2007 .

Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.

M. Ladanyi, M. Kris, V. Rusch, 2011, The Journal of thoracic and cardiovascular surgery.

Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer.

C. Sima, M. Kris, C. Azzoli, 2014, Cancer biomarkers : section A of Disease markers.

Weekly high-dose erlotinib in patients with non-small cell lung cancer (NSCLC): A phase I/II study.

M. Kris, C. Azzoli, V. Miller, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer

C. Azzoli, K. Russell, J. Hainsworth, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein

M. Kris, C. Azzoli, J. Crapanzano, 2005, Cancer.

Retrospective Study to Examine Prognostic Value of C-Reactive Protein in Patients With Surgically Resectable Non-Small-Cell Lung Cancer.

C. Azzoli, M. Duh, L. Huynh, 2023, Clinical lung cancer.

Clinical Outcomes with Perioperative Chemotherapy in Sarcomatoid Carcinomas of the Lung

C. Sima, M. Kris, C. Azzoli, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy.

S. Digumarthy, C. Azzoli, M. Mino‐Kenudson, 2017, International journal of radiation oncology, biology, physics.

Recurrent non-small cell lung cancer: evaluation of CT-guided radiofrequency ablation as salvage therapy

Kenneth E Rosenzweig, William Alago, K. Rosenzweig, 2012, Acta radiologica.

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy

C. Azzoli, K. Kelly, J. R. Pereira, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation.

C. Azzoli, P. Jänne, J. Neal, 2010 .

TRAIL agonists rescue mice from radiation-induced lung injury

C. Azzoli, D. Wazer, T. Dipetrillo, 2023, bioRxiv.

Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).

C. Azzoli, J. Meyerhardt, C. Fuchs, 2016 .

Abstract CT048: Phase 1/2 study of olaparib tablets and temozolomide in patients with small cell lung cancer (SCLC) following failure of prior chemotherapy

C. Azzoli, D. Haber, L. Sequist, 2017 .

Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.

A. Drilon, C. Sima, M. Kris, 2012 .

P-752 Biomarkers for small cell lung cancer (SCLC): DNA methylationand GD2 synthase transcript levels

M. Kris, C. Azzoli, L. Krug, 2005 .

Superiority of Carboplatin-Based Doublets to Cisplatin-Based Doublets among Medicare Patients Aged 70 and Older with Advanced Lung Cancer

E. Lamont, C. Azzoli, N. Keating, 2018 .

Chemotherapy for early stage non-small cell lung cancer.

M. Kris, C. Azzoli, 2001, Lung cancer.

Non-Small Cell Lung Cancer

C. Azzoli, 2009 .

Management of patients with resectable stage IIIA (N2) NSCLC

C. Azzoli, 2006, Journal of surgical oncology.

Bilateral acute simultaneous onset anterior uveitis presumed secondary to erlotinib: A report of two cases

C. Azzoli, Kendra A. Klein, L. Rifkin, 2016, American journal of ophthalmology case reports.

Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

M. Kris, C. Azzoli, W. Pao, 2005 .

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations.

M. Kris, C. Azzoli, Gregory Riely, 2009, Journal of Clinical Oncology.

Thoracic nuclear protein in testis (NUT) carcinoma: expanded pathological spectrum with expression of thyroid transcription factor‐1 and neuroendocrine markers

C. Azzoli, M. Mino‐Kenudson, J. Lennerz, 2021 .

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).

C. Azzoli, M. Mino‐Kenudson, L. Sequist, 2015 .

C-kit protein expression in tumor specimens as a predictor of sensitivity to imatinib mesylate in patients with small cell lung cancer (SCLC): A phase II clinical trial.

M. Kris, C. Azzoli, J. Crapanzano, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

M. Kris, C. Azzoli, W. Pao, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy

C. Azzoli, K. Kelly, J. R. Pereira, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer

Julie M. Batten, S. Digumarthy, A. Iafrate, 2018, JCO precision oncology.

G. Giaccone, C. Azzoli, R. Govindan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer

C. Rudin, M. Kris, C. Azzoli, 2007 .